newsfilter
← Latest News
GlobeNewswire·

Prometheus Biosciences Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Progress

- Full clinical trial results from Phase 1a trial of PRA023 and announcement of a third Phase 2 indication for PRA023 expected in fourth quarter 2021 - - Enrollment on track for Phase 2 in ulcerative colitis and Phase 2a in Crohn's disease wit